Guglielmo Di Molfetta

1 month ago | alz-journals.onlinelibrary.wiley.com | Nicholas Ashton |Andrea L. Benedet |Guglielmo Di Molfetta |Ilaria Pola

1 BACKGROUND Discovery plasma proteomics has long since demonstrated a differential signal in the blood of patients clinically diagnosed with Alzheimer's disease (AD).1, 2 These earlier studies used agnostic methods to discover novel biomarkers—proteomic technologies not predicated on any a priori hypotheses in a case-control approach1, 3-6 but later evolved to an endophenotype design based on pathology; brain atrophy measures,1, 7-9 cerebrospinal fluid (CSF) biomarkers,10 or amyloid beta...

Jul 29, 2024 | medrxiv.org | Nicholas Ashton |Andrea L. Benedet |Ilaria Pola |Guglielmo Di Molfetta

HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon,...